应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
RDN Radian Group Inc
盘前交易 03-19 08:03:28 EDT
32.77
-0.29
-0.88%
最高
33.14
最低
32.44
成交量
150.61万
今开
32.56
昨收
33.06
日振幅
2.12%
总市值
44.66亿
流通市值
43.82亿
总股本
1.36亿
成交额
4,941万
换手率
1.13%
流通股本
1.34亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
百心安-B(02185)：Iberis®RDN系统在泰国完成注册
智通财经 · 03-17 22:40
百心安-B(02185)：Iberis®RDN系统在泰国完成注册
百心安-B(02185)：IBERIS® RDN系统在印度尼西亚洲注册
智通财经 · 01-26
百心安-B(02185)：IBERIS® RDN系统在印度尼西亚洲注册
Radian Group Inc预计2026年2月完成Inigo收购案，最终交割需满足常规条件——SEC文件披露
美股速递 · 2025-12-30
Radian Group Inc预计2026年2月完成Inigo收购案，最终交割需满足常规条件——SEC文件披露
港股异动 | 百心安-B(02185)现涨超4% IBERIS RDN系统近日在新西兰注册
智通财经网 · 2025-12-08
港股异动 | 百心安-B(02185)现涨超4% IBERIS RDN系统近日在新西兰注册
港股异动 | 百心安-B(02185)午后涨近12% IBERIS® RDN系统在新西兰注册
智通财经 · 2025-11-27
港股异动 | 百心安-B(02185)午后涨近12% IBERIS® RDN系统在新西兰注册
百心安-B(02185)：IBERIS® RDN系统在新西兰注册
智通财经 · 2025-11-26
百心安-B(02185)：IBERIS® RDN系统在新西兰注册
百心安-B(02185)：IBERIS® RDN系统在英国注册
智通财经 · 2025-10-30
百心安-B(02185)：IBERIS® RDN系统在英国注册
港股异动 | 百心安-B(02185)涨超4% IBERIS? RDN系统在瑞士完成市场准入及首例商业化手术
中金财经 · 2025-10-24
港股异动 | 百心安-B(02185)涨超4% IBERIS? RDN系统在瑞士完成市场准入及首例商业化手术
百心安-B(02185)：IBERIS® RDN系统在瑞士完成市场准入及首例商业化手术
智通财经 · 2025-10-23
百心安-B(02185)：IBERIS® RDN系统在瑞士完成市场准入及首例商业化手术
中金：全球医疗器械市场稳健增长 电生理、RDN等8个细分赛道值得重点关注
智通财经 · 2025-10-23
中金：全球医疗器械市场稳健增长 电生理、RDN等8个细分赛道值得重点关注
港股异动 | 百心安-B(02185)再涨近10% 旗下Iberis RDN系统先发优势明显 公司商业化进程有望加速
智通财经 · 2025-10-06
港股异动 | 百心安-B(02185)再涨近10% 旗下Iberis RDN系统先发优势明显 公司商业化进程有望加速
百心安-B现涨逾19% 附属研发的Iberis®RDN系统在德国完成首例商业化手术
新浪港股 · 2025-03-04
百心安-B现涨逾19% 附属研发的Iberis®RDN系统在德国完成首例商业化手术
港股异动 | 百心安-B(02185)早盘涨超21% 附属研发的Iberis®RDN系统在德国完成首例商业化手术
智通财经 · 2025-03-04
港股异动 | 百心安-B(02185)早盘涨超21% 附属研发的Iberis®RDN系统在德国完成首例商业化手术
百心安-B早盘大涨逾31% 国家药监局批准IBERIS®RDN系统注册
新浪港股 · 2025-02-27
百心安-B早盘大涨逾31% 国家药监局批准IBERIS®RDN系统注册
港股异动 | 百心安-B(02185)大涨超31% 国家药监局批准IBERIS®RDN系统注册
智通财经 · 2025-02-27
港股异动 | 百心安-B(02185)大涨超31% 国家药监局批准IBERIS®RDN系统注册
【百心安-B(02185.HK)：国家药监局批准IBERIS®RDN系统注册】百心安-B(02185.HK)发布公告，于2025年2月26日，公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis®多极肾动脉射频消融系统(包括一次性使用多极肾动脉射频消融导管及肾动脉射频消融仪)(Iberis®RDN系统)，已获中国国家药品监督管理局批准，用于辅助治疗难治性高血压及药物不耐受的高血压患者。
金融界 · 2025-02-26
【百心安-B(02185.HK)：国家药监局批准IBERIS®RDN系统注册】百心安-B(02185.HK)发布公告，于2025年2月26日，公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis®多极肾动脉射频消融系统(包括一次性使用多极肾动脉射频消融导管及肾动脉射频消融仪)(Iberis®RDN系统)，已获中国国家药品监督管理局批准，用于辅助治疗难治性高血压及药物不耐受的高血压患者。
百心安-B(02185)：国家药监局批准IBERIS®RDN系统注册
智通财经 · 2025-02-26
百心安-B(02185)：国家药监局批准IBERIS®RDN系统注册
瑞银：维持Radian Group(RDN.US)评级，由中性调整至中性评级, 目标价由33.00美元调整至34.00美元。
金融界 · 2025-02-19
瑞银：维持Radian Group(RDN.US)评级，由中性调整至中性评级, 目标价由33.00美元调整至34.00美元。
瑞迪安集团2024财年实现净利润6.04亿美元，同比增加0.17%
市场透视 · 2025-02-09
瑞迪安集团2024财年实现净利润6.04亿美元，同比增加0.17%
异动解读 | 业绩超预期,Radian盘后股价大涨5.17%
异动解读 · 2025-02-06
异动解读 | 业绩超预期,Radian盘后股价大涨5.17%
加载更多
公司概况
公司名称：
Radian Group Inc
所属市场：
NYSE
上市日期：
--
主营业务：
Radian Group Inc.，作为美国领先的私人抵押贷款保险公司，提供解决方案，扩大人们获得负担得起、负责任和可持续的住房的机会，并帮助借款人实现拥有住房的梦想。该公司有一个可报告的业务部门，抵押贷款保险。抵押贷款保险部门主要通过住宅第一留置权抵押贷款的私人抵押贷款保险，汇总、管理和分配美国抵押贷款信贷风险，以造福抵押贷款机构和抵押贷款信贷投资者。
发行价格：
--
{"stockData":{"symbol":"RDN","market":"US","secType":"STK","nameCN":"Radian Group Inc","latestPrice":32.77,"timestamp":1773864000000,"preClose":33.06,"halted":0,"volume":1506144,"delay":0,"changeRate":-0.008771929824561377,"floatShares":133715935,"shares":136272409,"eps":4.137612,"marketStatus":"盘前交易","change":-0.29,"latestTime":"03-19 08:03:28 EDT","open":32.56,"high":33.14,"low":32.4405,"amount":49412367.4368,"amplitude":0.021158,"askPrice":33.06,"askSize":1,"bidPrice":32.13,"bidSize":2,"shortable":3,"etf":0,"ttmEps":4.137612,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773927000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":717912000000,"exchange":"NYSE","adjPreClose":32.77,"dividendRate":0.031126,"postHourTrading":{"tag":"盘后","latestPrice":32.77,"preClose":32.77,"latestTime":"16:10 EDT","volume":143373,"amount":4698333.21,"timestamp":1773864605054,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1251399399495696,"impliedVol":0.1702,"impliedVolPercentile":0.252},"requestUrl":"/m/hq/s/RDN","defaultTab":"news","newsList":[{"id":"2620759804","title":"百心安-B(02185)：Iberis®RDN系统在泰国完成注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2620759804","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620759804?lang=zh_cn&edition=full","pubTime":"2026-03-17 22:40","pubTimestamp":1773758458,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百心安-B 发布公告，最近，公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis多极肾动脉射频消融导管系统已在泰国完成注册。安通与柏盛就IberisRDN系统的商业化达成战略伙伴关系，相关合作涵盖多个地区，包括但不限于欧盟国家、亚太地区及拉丁美洲地区。截至本公告日期，IberisRDN系统是全球唯一获准使用经桡动脉方法和经股动脉入路方法的肾神经阻断产品。安通已于2016年于欧洲取得IberisRDN系统的CE标志。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4229","BK4195","02185","LU0154245756.USD","BK1100","LU0154245673.USD","RDN"],"gpt_icon":0},{"id":"2606008248","title":"百心安-B(02185)：IBERIS® RDN系统在印度尼西亚洲注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2606008248","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606008248?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:17","pubTimestamp":1769433461,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百心安-B 发布公告，最近，本公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis多极肾动脉射频消融导管系统已在印度尼西亚注册。安通与柏盛就IberisRDN系统的商业化达成战略伙伴关系，相关合作涵盖多个地区，包括但不限于欧盟国家、亚太地区及拉丁美洲地区。截至本公告日期，IberisRDN系统是全球唯一获准使用经桡动脉方法和经股动脉入路方法的肾神经阻断产品。集团的最终目标是为全球患者提供门诊RDN手术。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02185","BK1100","BK4229","LU0154245673.USD","RDN","BK4195","LU0154245756.USD"],"gpt_icon":0},{"id":"1151120255","title":"Radian Group Inc预计2026年2月完成Inigo收购案，最终交割需满足常规条件——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1151120255","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151120255?lang=zh_cn&edition=full","pubTime":"2025-12-30 05:55","pubTimestamp":1767045312,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新文件显示，Radian Group Inc计划于2026年2月完成对Inigo的收购交易。该时间节点取决于交易双方能否满足行业惯例中的各项交割前提条件。\n若所有条款顺利达成，这笔备受市场关注的并购案将按既定时间表落地。不过，最终交割仍存在因条件未满足而调整时间线的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","RDN","LU0154245756.USD","LU0154245673.USD","BK4229"],"gpt_icon":0},{"id":"2589385800","title":"港股异动 | 百心安-B(02185)现涨超4% IBERIS RDN系统近日在新西兰注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2589385800","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589385800?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:46","pubTimestamp":1765165568,"startTime":"0","endTime":"0","summary":"百心安-B(02185)现涨超4%，截至发稿，涨4.13%，报6.56港元，成交额118.24万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20251208/20251208114745_76311.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251208/20251208114745_76311.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02185","LU0154245756.USD","BK4229","RDN","BK4195","LU0154245673.USD","BK1100"],"gpt_icon":0},{"id":"2586219151","title":"港股异动 | 百心安-B(02185)午后涨近12% IBERIS® RDN系统在新西兰注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2586219151","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586219151?lang=zh_cn&edition=full","pubTime":"2025-11-27 13:42","pubTimestamp":1764222133,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百心安-B午后涨近12%，截至发稿，涨11.93%，报6.85港元，成交额430.19万港元。消息面上，11月26日，百心安-B发布公告，最近，公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis多极肾动脉射频消融导管系统已在新西兰完成新西兰药品和医疗器械安全管理局的注册。公司的最终目标是为全球患者提供门诊RDN手术。安通已于2016年于欧洲取得Iberis RDN系统的CE标志。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RDN","02185","LU0154245673.USD","BK1100","LU0154245756.USD","BK4195","BK4229"],"gpt_icon":0},{"id":"2586199256","title":"百心安-B(02185)：IBERIS® RDN系统在新西兰注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2586199256","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586199256?lang=zh_cn&edition=full","pubTime":"2025-11-26 19:16","pubTimestamp":1764155774,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百心安-B(02185)发布公告，最近，公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis®多极肾动脉射频消融导管系统(Iberis® RDN系统)已在新西兰完成新西兰药品和医疗器械安全管理局(Medsafe)的注册。截至本公告日期，Iberis® RDN系统是全球唯一获准使用经桡动脉方法(TRA)和经股动脉入路方法(TFA)的肾神经阻断(RDN)产品。TRA使RDN更安全、更有效、更便宜。公司的最终目标是为全球患者提供门诊RDN手术。安通已于2016年于欧洲取得Iberis® RDN系统的CE标志。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK4195","LU0154245673.USD","LU0154245756.USD","BK4229","RDN","02185"],"gpt_icon":0},{"id":"2579231761","title":"百心安-B(02185)：IBERIS® RDN系统在英国注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2579231761","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579231761?lang=zh_cn&edition=full","pubTime":"2025-10-30 22:12","pubTimestamp":1761833549,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百心安-B 发布公告，最近，本公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis多极肾动脉射频消融导管系统已在英国完成药品和健康产品监管局的注册。安通与柏盛就IberisRDN系统的商业化达成战略伙伴关系，相关合作涵盖多个地区，包括但不限于欧盟国家、亚太地区及拉丁美洲地区。TRA使RDN更安全、更有效、更便宜。集团的最终目标是为全球患者提供门诊RDN手术。安通已于2016年于欧洲取得Iberis RDN系统的CE标志。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","LU0154245756.USD","LU0154245673.USD","RDN","BK4229","BK4195","02185"],"gpt_icon":0},{"id":"2577550224","title":"港股异动 | 百心安-B(02185)涨超4% IBERIS? RDN系统在瑞士完成市场准入及首例商业化手术","url":"https://stock-news.laohu8.com/highlight/detail?id=2577550224","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577550224?lang=zh_cn&edition=full","pubTime":"2025-10-24 11:27","pubTimestamp":1761276421,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百心安-B涨超4%，截至发稿，涨4.57%，报7.78港元，成交额455.41万港元。 消息面上，10月23日，百心安-B发布公告，最近，公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis多极肾动脉射频消融系统在瑞士完成市场准入及首例商业化手术。该手术由巴塞尔大学医院进行。 截至本公告日期，IberisRDN系统是全球唯一获准使用经桡动脉方法和经股动脉入路方法的肾神经阻断产品。公司的最终目标是为全球患者提供门诊RDN手术。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251024/31733521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02185","RDN","BK4229","BK1100","LU0154245756.USD","LU0154245673.USD","BK4195"],"gpt_icon":0},{"id":"2577730936","title":"百心安-B(02185)：IBERIS® RDN系统在瑞士完成市场准入及首例商业化手术","url":"https://stock-news.laohu8.com/highlight/detail?id=2577730936","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577730936?lang=zh_cn&edition=full","pubTime":"2025-10-23 19:46","pubTimestamp":1761220013,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百心安-B 发布公告，最近，公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis多极肾动脉射频消融系统在瑞士完成市场准入及首例商业化手术。安通与柏盛就IberisRDN系统的商业化达成战略伙伴关系，相关合作涵盖多个地区，包括但不限于欧盟国家、亚太地区及拉丁美洲地区。公司的最终目标是为全球患者提供门诊RDN手术。安通已于2016年于欧洲取得IberisRDN系统的CE标志。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4229","02185","RDN","BK4195","LU0154245756.USD","LU0154245673.USD","BK1100"],"gpt_icon":0},{"id":"2577730363","title":"中金：全球医疗器械市场稳健增长 电生理、RDN等8个细分赛道值得重点关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2577730363","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577730363?lang=zh_cn&edition=full","pubTime":"2025-10-23 15:34","pubTimestamp":1761204889,"startTime":"0","endTime":"0","summary":"中金主要观点如下：全球医疗器械市场稳健增长根据QY Research数据，基于人口老龄化、慢性病患病率上升、医疗技术进步、政策支持以及医疗服务体系的不断完善等，全球医疗器械市场规模2030年可达8,626亿美元，2025E-2030ECAGR为5%。估值体系：增长质量决定溢价中金尝试对全球15家医疗器械头部企业的主营业务、增速和估值进行了梳理，发现心血管、医学影像、外科、骨科、血糖管理和神经科学是较多企业聚焦的细分赛道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK4229","RDN","BK1100","LU0154245673.USD","LU0154245756.USD","BK1574","09997","159883","BK1222","BK1583","BK4195"],"gpt_icon":0},{"id":"2573624127","title":"港股异动 | 百心安-B(02185)再涨近10% 旗下Iberis RDN系统先发优势明显 公司商业化进程有望加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2573624127","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2573624127?lang=zh_cn&edition=full","pubTime":"2025-10-06 14:44","pubTimestamp":1759733040,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百心安-B再涨近10%，截至发稿，涨9.94%，报7.85港元，成交额1175.87万港元。该行指出，百心安 Iberis RDN 系统是全球唯一获批上市能兼具经桡动脉和经股动脉双入路 RDN，先发优势显著，国内已与远大健康、海外多国家地区联合蓝帆柏盛达成重磅战略合作；德国、法国已将 Iberis RDN 纳入医保，当前正为百心安商业化加速起点，建议关注百心安。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1352378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0154245756.USD","BK4229","BK4195","YANG","LU0154245673.USD","BK1100","02185","BK4614","RDN"],"gpt_icon":1},{"id":"2516340613","title":"百心安-B现涨逾19% 附属研发的Iberis®RDN系统在德国完成首例商业化手术","url":"https://stock-news.laohu8.com/highlight/detail?id=2516340613","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516340613?lang=zh_cn&edition=full","pubTime":"2025-03-04 11:28","pubTimestamp":1741058880,"startTime":"0","endTime":"0","summary":" 百心安-B早盘一度涨超21%，截至发稿，股价现涨18.82%，报2.21港元，成交额101.54万港元。 消息面上，3月3日，百心安-B发布公告，于2025年2月，该公司附属公司上海安通医疗科技有限公司（安通）研发的Iberis多极肾动脉射频消融系统在德国完成首例商业化手术。该手术由University Hospital of Saarland的Saarraaken Kulenthiran博士所领导的团队进行。概无有关并发症或不良事件的报导。该案例得到柏盛国际集团有限公司（柏盛）及安通的共同支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-04/doc-inenncvt5569400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["RDN","BK4229","LU0154245673.USD","02185","BK4195","LU0154245756.USD","BK1100"],"gpt_icon":0},{"id":"2516904826","title":"港股异动 | 百心安-B(02185)早盘涨超21% 附属研发的Iberis®RDN系统在德国完成首例商业化手术","url":"https://stock-news.laohu8.com/highlight/detail?id=2516904826","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516904826?lang=zh_cn&edition=full","pubTime":"2025-03-04 10:54","pubTimestamp":1741056888,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百心安-B早盘涨超21%，截至发稿，涨21.51%，报2.26港元，成交额91.5万港元。消息面上，3月3日，百心安-B发布公告，于2025年2月，该公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis多极肾动脉射频消融系统在德国完成首例商业化手术。公司的最终目标是为全球患者提供门诊RDN手术。安通已于2016年于欧洲取得IberisRDN系统的CE标志，并正在进行一项上市后临床试验，即“RADIUS-HTN”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4229","02185","RDN","BK4195","LU0154245756.USD","LU0154245673.USD","BK1100"],"gpt_icon":0},{"id":"2514179608","title":"百心安-B早盘大涨逾31% 国家药监局批准IBERIS®RDN系统注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2514179608","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514179608?lang=zh_cn&edition=full","pubTime":"2025-02-27 11:11","pubTimestamp":1740625860,"startTime":"0","endTime":"0","summary":" 百心安-B早盘大涨超31%，截至发稿，股价上涨30.53%，现报2.48港元，成交额331.97万港元。 百心安公布，2月26日，公司附属公司上海安通医疗科技有限公司研发的Iberis多极肾动脉射频消融系统，已获中国国家药品监督管理局批准，用于辅助治疗难治性高血压及药物不耐受的高血压患者。 德邦证券此前研报指出，Iberis 为全球唯一可以提供两种介入方式的肾动脉消融产品，且具备较细的导管鞘尺寸，有望凭借先发优势和强有力的产品性能迅速抢占市场。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-27/doc-inemwuek7213572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1100","02185","BK4195","LU0154245756.USD","LU0154245673.USD","BK4229","RDN"],"gpt_icon":0},{"id":"2514814773","title":"港股异动 | 百心安-B(02185)大涨超31% 国家药监局批准IBERIS®RDN系统注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2514814773","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514814773?lang=zh_cn&edition=full","pubTime":"2025-02-27 10:42","pubTimestamp":1740624166,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百心安-B(02185)大涨超31%，截至发稿，涨31.58%，报2.5港元，成交额302.21万港元。消息面上，百心安公布，2月26日，公司附属公司上海安通医疗科技有限公司研发的Iberis®多极肾动脉射频消融系统(包括一次性使用多极肾动脉射频消融导管及肾动脉射频消融仪)(Iberis®RDN系统)，已获中国国家药品监督管理局批准，用于辅助治疗难治性高血压及药物不耐受的高血压患者。德邦证券此前研报指出，Iberis 为全球唯一可以提供两种介入方式的肾动脉消融产品，且具备较细的导管鞘尺寸，有望凭借先发优势和强有力的产品性能迅速抢占市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK4195","LU0154245673.USD","LU0154245756.USD","BK4229","RDN","02185"],"gpt_icon":0},{"id":"2514992889","title":"【百心安-B(02185.HK)：国家药监局批准IBERIS®RDN系统注册】百心安-B(02185.HK)发布公告，于2025年2月26日，公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis®多极肾动脉射频消融系统(包括一次性使用多极肾动脉射频消融导管及肾动脉射频消融仪)(Iberis®RDN系统)，已获中国国家药品监督管理局批准，用于辅助治疗难治性高血压及药物不耐受的高血压患者。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514992889","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514992889?lang=zh_cn&edition=full","pubTime":"2025-02-26 17:11","pubTimestamp":1740561096,"startTime":"0","endTime":"0","summary":"百心安-B(02185.HK)发布公告，于2025年2月26日，公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis®多极肾动脉射频消融系统(包括一次性使用多极肾动脉射频消融导管及肾动脉射频消融仪)(Iberis®RDN系统)，已获中国国家药品监督管理局批准，用于辅助治疗难治性高血压及药物不耐受的高血压患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26171148403723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1100","LU0154245756.USD","159891","LU0154245673.USD","02185","BK4195","BK4229","RDN"],"gpt_icon":0},{"id":"2514886077","title":"百心安-B(02185)：国家药监局批准IBERIS®RDN系统注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2514886077","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514886077?lang=zh_cn&edition=full","pubTime":"2025-02-26 17:06","pubTimestamp":1740560791,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百心安-B(02185)发布公告，于2025年2月26日，公司附属公司上海安通医疗科技有限公司(安通)研发的Iberis®多极肾动脉射频消融系统(包括一次性使用多极肾动脉射频消融导管及肾动脉射频消融仪)(Iberis®RDN系统)，已获中国国家药品监督管理局批准，用于辅助治疗难治性高血压及药物不耐受的高血压患者。Iberis®RDN系统关键试验(Iberis-HTN)的详细结果已发表于Circulation。安通已于2016年于欧洲为Iberis®RDN系统获得CE标志。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02185","RDN","BK4195","LU0154245673.USD","BK4229","BK1100","LU0154245756.USD"],"gpt_icon":0},{"id":"2512488305","title":"瑞银：维持Radian Group(RDN.US)评级，由中性调整至中性评级, 目标价由33.00美元调整至34.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512488305","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512488305?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:31","pubTimestamp":1739975484,"startTime":"0","endTime":"0","summary":"瑞银：维持Radian Group(RDN.US)评级，由中性调整至中性评级, 目标价由33.00美元调整至34.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19223148266867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RDN"],"gpt_icon":0},{"id":"2510051127","title":"瑞迪安集团2024财年实现净利润6.04亿美元，同比增加0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510051127","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510051127?lang=zh_cn&edition=full","pubTime":"2025-02-09 00:01","pubTimestamp":1739030490,"startTime":"0","endTime":"0","summary":"2月9日，瑞迪安集团公布财报，公告显示公司2024财年净利润为6.04亿美元，同比增加0.17%；其中营业收入为12.90亿美元，同比增加3.95%，每股基本收益为3.96美元。从资产负债表来看，瑞迪安集团总负债40.04亿美元，其中短期债务--，资产负债比为2.16，流动比率为3.52。机构评级：截至2025年2月9日，当前有7家机构对瑞迪安集团目标价做出预测，其中目标均价为36.29美元，其中最低目标价为33.00美元，最高目标价为40.00美元。抵押贷款部门获得了大部分收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250209000142a23e5b85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250209000142a23e5b85&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RDN"],"gpt_icon":0},{"id":"1183359743","title":"异动解读 | 业绩超预期,Radian盘后股价大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183359743","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183359743?lang=zh_cn&edition=full","pubTime":"2025-02-06 06:14","pubTimestamp":1738793663,"startTime":"0","endTime":"0","summary":"Radian集团昨日盘后股价大涨5.17%,引起市场广泛关注。这一股价强劲上涨或与公司2024年第四季度业绩超出市场预期有关。数据显示,Radian公司2024年第四季度每股盈利0.98美元,高于分析师预期的0.92美元,同比去年增长2.08%。对于Radian来说,两个核心业务版块包括担保保险以及房地产服务业务。分析人士表示,随着房地产市场稳步复苏,Radian公司在抵押贷款担保市场的份额提升,加上房地产服务收入的稳步增长,推动公司整体业绩实现了大幅跃升。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RDN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.radian.com","stockEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":-0.0015},{"period":"3month","weight":-0.1136},{"period":"6month","weight":-0.1198},{"period":"1year","weight":0.043},{"period":"ytd","weight":-0.0895}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Radian Group Inc.，作为美国领先的私人抵押贷款保险公司，提供解决方案，扩大人们获得负担得起、负责任和可持续的住房的机会，并帮助借款人实现拥有住房的梦想。该公司有一个可报告的业务部门，抵押贷款保险。抵押贷款保险部门主要通过住宅第一留置权抵押贷款的私人抵押贷款保险，汇总、管理和分配美国抵押贷款信贷风险，以造福抵押贷款机构和抵押贷款信贷投资者。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.001381},{"month":2,"riseRate":0.529412,"avgChangeRate":0.013826},{"month":3,"riseRate":0.529412,"avgChangeRate":0.036641},{"month":4,"riseRate":0.484848,"avgChangeRate":-0.000082},{"month":5,"riseRate":0.636364,"avgChangeRate":0.026674},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.036877},{"month":7,"riseRate":0.545455,"avgChangeRate":0.035079},{"month":8,"riseRate":0.575758,"avgChangeRate":0.076552},{"month":9,"riseRate":0.575758,"avgChangeRate":0.025069},{"month":10,"riseRate":0.636364,"avgChangeRate":-0.002621},{"month":11,"riseRate":0.411765,"avgChangeRate":-0.007341},{"month":12,"riseRate":0.588235,"avgChangeRate":0.059907}],"exchange":"NYSE","name":"Radian Group Inc","nameEN":"Radian"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Radian Group Inc(RDN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Radian Group Inc(RDN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Radian Group Inc,RDN,Radian Group Inc股票,Radian Group Inc股票老虎,Radian Group Inc股票老虎国际,Radian Group Inc行情,Radian Group Inc股票行情,Radian Group Inc股价,Radian Group Inc股市,Radian Group Inc股票价格,Radian Group Inc股票交易,Radian Group Inc股票购买,Radian Group Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Radian Group Inc(RDN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Radian Group Inc(RDN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}